Linklaters advises on Hutchison China MediTech’s proposed listing on the Hong Kong Stock Exchange

Linklaters is advising Goldman Sachs (Asia) LLC and Merrill Lynch Far East Limited as joint sponsors to the proposed Hong Kong listing of Hutchison China MediTech Limited (Chi-Med).

Chi-Med filed Form A1 with the Hong Kong Stock Exchange on 15 April 2019. Currently, Chi-Med’s shares are admitted for trading on the AIM market of the London Stock Exchange, and its American Depositary Shares (ADSs) are listed on the Nasdaq Global Select Market. Upon listing on the Hong Kong Stock Exchange, Chi-Med will be triple listed.

Chi-Med (AIM/Nasdaq: HCM) is a commercial-stage biopharmaceutical company focused on discovery, development and commercialisation of targeted therapies and immunotherapies for oncology and immunological diseases. Chi-Med is 60.2% owned by CK Hutchison Holdings Limited and it is expected that CK Hutchison’s stake will reduce to below 50% upon the listing.

The Linklaters team is led by corporate partners Robert Cleaver and Kevin Cheung as well as managing associate Tiffany Yan.